Claes Thulin leaving BioPhausia

Claes Thulin leaving BioPhausia


BioPhausia's CEO Claes Thulin is leaving his post in order to pursue entrepreneurial activities. The change of CEO is supported by the Board, which has already started the process of recruiting a successor. With Claes Thulin at the helm, BioPhausia evolved from a small research company into a successful pharmaceutical company occupying a strong market position.

"As Claes leaves his position, with the full support of the Board, we would take this opportunity to thank him for his sterling work during his years as CEO," says BioPhausia's Chairman of the Board Jan Rynning. Mr. Thulin has offered to stay on as CEO until a successor is in place."

After eight years as CEO I want to try something different, and intend topursue entrepreneurial activities in the area of pharmaceuticals," he explains. For more information, please contact: Jan Rynning, Chairman of the Board, tel. +46 (0)703510005 Claes Thulin, CEO, tel. +46 (0)8 4076430

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.